MP61-08 THE PRESENCE OF ANTIBODIES AGAINST THE AD2 EPITOPE OF CYTOMEGALOVIRUS GLYCOPROTEIN B IS ASSOCIATED WITH ACUTE REJECTION AFTER RENAL TRANSPLANTATION

Abstract

You have accessJournal of UrologyTransplantation & Vascular Surgery: Renal Transplantation & Vascular Surgery I1 Apr 2018MP61-08 THE PRESENCE OF ANTIBODIES AGAINST THE AD2 EPITOPE OF CYTOMEGALOVIRUS GLYCOPROTEIN B IS ASSOCIATED WITH ACUTE REJECTION AFTER RENAL TRANSPLANTATION Akihumi Onagi, Kei Ishibashi, Ryo Tanji, Ruriko Takinami, Kanako Matsuoka, Tomoyuki Koguchi, Seiji Hoshi, Junya Hata, Yuichi Sato, Hidenori Akaihata, Masao Kataoka, Soichiro Ogawa, Nobihuro Haga, Ken Aikawa, and Yoshiyuki Kojima Akihumi OnagiAkihumi Onagi More articles by this author , Kei IshibashiKei Ishibashi More articles by this author , Ryo TanjiRyo Tanji More articles by this author , Ruriko TakinamiRuriko Takinami More articles by this author , Kanako MatsuokaKanako Matsuoka More articles by this author , Tomoyuki KoguchiTomoyuki Koguchi More articles by this author , Seiji HoshiSeiji Hoshi More articles by this author , Junya HataJunya Hata More articles by this author , Yuichi SatoYuichi Sato More articles by this author , Hidenori AkaihataHidenori Akaihata More articles by this author , Masao KataokaMasao Kataoka More articles by this author , Soichiro OgawaSoichiro Ogawa More articles by this author , Nobihuro HagaNobihuro Haga More articles by this author , Ken AikawaKen Aikawa More articles by this author , and Yoshiyuki KojimaYoshiyuki Kojima More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2018.02.1987AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Cytomegalovirus (CMV) is a risk factor for acute renal allograft rejection. The aim of this study was to evaluate the association between antibodies against CMV glycoprotein B (gB) and acute rejection after transplantation. METHODS A total of 77 consecutive renal transplant recipients in a D+/R+ setting who were managed by a preemptive strategy were included and followed up for 6 months after transplantation. DNA fragments encoding the gB AD2 epitopes of CMV were synthesized and expressed in Escherichia coli as GST fusion proteins using the pGEX-5X-3 vector system. Presence of antibodies against CMV gB AD2 epitope in D+/R+ renal transplantation cases were determined by ELISA. The CMV gB AD2 serology and clinical outcomes were analyzed retrospectively. RESULTS Biopsy-proven rejection was confirmed in 35% of the recipients. Among them, 85% had antibodies against CMV gB AD2. The rate of acute rejection was significantly higher in the recipients who had antibodies against gB than in those who did not. Although our previous study demonstrated that the mismatch of gH serotypes was a risk factor for renal transplantation, there was no difference in the seroprevalence against gB AD2 between the gH-type-matched and -mismatched recipients with acute rejection. CONCLUSIONS Antibodies against gB AD2 can be a useful indicator to predict acute rejection in transplantation in a D+/R+ setting in addition to antibodies against the mismatched gH types. © 2018FiguresReferencesRelatedDetails Volume 199Issue 4SApril 2018Page: e826 Advertisement Copyright & Permissions© 2018MetricsAuthor Information Akihumi Onagi More articles by this author Kei Ishibashi More articles by this author Ryo Tanji More articles by this author Ruriko Takinami More articles by this author Kanako Matsuoka More articles by this author Tomoyuki Koguchi More articles by this author Seiji Hoshi More articles by this author Junya Hata More articles by this author Yuichi Sato More articles by this author Hidenori Akaihata More articles by this author Masao Kataoka More articles by this author Soichiro Ogawa More articles by this author Nobihuro Haga More articles by this author Ken Aikawa More articles by this author Yoshiyuki Kojima More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...